Short answer
Steris (STE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.6B (up 8.8% year over year) with net income of $214M.
Q3 2026 key financials · XBRL
- Revenue
- $1.6B
- +8.8% YoY · +6.4% QoQ
- Net income
- $214M
- +11.4% YoY · +6.8% QoQ
- Operating margin
- 18.5%
- Gross margin
- 44.7%
Source: XBRL data from the Steris (STE) Q3 2026 10-Q on SEC EDGAR. USD.
Steris Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $1,588.6M, up 8.8% YoY from $1,460.3M
- Gross margin 44.7% vs 44.2% YoY; operating income $294.3M vs $265.8M
- Best segment Life Sciences: revenue $170.6M, up 17.7%; margin 44.4% vs 41.3%
- Healthcare weakest margin trend: 24.0% vs 25.1%, despite revenue growth of 8.6% to $1,122.4M
- Six-month operating cash flow $656.1M vs $707.8M; free cash flow $492.5M vs $527.7M, with $200.0M share repurchases
Risk Factors
- New transaction risk: Xodus Medical Acquisition could fail to close, with termination permitted after July 12, 2027
- Regulatory risk: Hart-Scott-Rodino approval and other antitrust clearances could require divestitures or remedies
- Operational risk: Acquisition uncertainty could cause employee departures and customer, supplier, or partner disruptions
- Financial risk: Approximately $2.0 billion additional debt expected, versus $1.9 billion outstanding at September 30, 2026
- Financing risk: Bridge facility may carry higher costs and shorter maturities if permanent financing terms prove unacceptable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Steris quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.